Brief: Netramark Announces Collaboration Agreement With Nimh To Analyze Clinical Trial Data On The Use Of Ketamine In Psychiatric Disorders
10/06/2024 13:56
June 10 (Reuters) - NetraMark Holdings Inc AIAI.CD :
* NETRAMARK ANNOUNCES COLLABORATION AGREEMENT WITH NIMH TO
ANALYZE
CLINICAL TRIAL DATA ON THE USE OF KETAMINE IN PSYCHIATRIC
DISORDERS
Source text for Eikon: ID:nCNWBpx4qa
Further company coverage: AIAI.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NetraMark Holdings
See all newsBrief: Netramark Announces Uplisting To Toronto Stock Exchange
Brief: Netramark Signs Four New Contracts With A Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights
Brief: Asklepion Pharmaceuticals Signs Contract To Utilize Netramark Technology In Phase III Pediatric Cardiac Study
Brief: NetraMark Holdings Signs Contract With AlgoTx To Enhance Clinical Trial Design For ATX01
Brief: Netramark And Worldwide Clinical Trials Announce Agreement To Transform Clinical Trial Design With Ai-Powered Precision